Immune Pharmaceuticals Receives FDA Guidance for Phase III Pivotal Trial of its AML Therapy Ceplene In Combination with Low Dose IL2

NEW YORK Oct. 27 2016 PRNewswire Immune Pharmaceuticals NASDAQIMNP Immune announced today that it has received guidance from the United States Food and Drug Administration FDA on a phase III study for Ceplene in combination with low dose IL2 for the maint...